PMID: 9661016Jul 14, 1998Paper

Effects of DU-6859a, a new quinolone antimicrobial, on theophylline metabolism in in vitro and in vivo studies

Antimicrobial Agents and Chemotherapy
Y NikiO Okazaki

Abstract

In vitro and in vivo studies were conducted to investigate the drug interaction between a new quinolone antimicrobial, DU-6859a, and theophylline (TP). The effect of DU-6859a on TP metabolism was evaluated in vitro by measuring the rate of TP metabolite formation by using human liver microsomes. DU-6859a inhibited the metabolism of TP, especially the formation of 1-methylxanthine, in vitro, but to a lesser extent than other drugs that are known to interact with TP. TP was administered alone (200 mg twice a day [b.i.d.] for 9 days) or in combination with DU-6859a (50 or 100 mg b.i.d. for 5 days) to six healthy subjects. DU-6859a administered at a dose of 50 mg resulted in no changes in serum TP concentrations, and slight increases in serum TP concentrations were observed at a dose of 100 mg. Moreover, the administration of 100 mg of DU-6859a resulted in decreases in all urinary TP metabolites, with significant differences. It appears that although DU-6859a has a weak inhibitory effect on TP metabolism in vitro, its concomitant use with TP at clinical dosage levels does not cause any adverse effects, showing only a slight increase in blood TP concentrations and a decrease in urinary metabolites.

References

Nov 1, 1979·Clinical Pharmacology and Therapeutics·J J GrygielD J Birkett
Jul 1, 1992·Antimicrobial Agents and Chemotherapy·K SatoY Osada
Jan 1, 1992·Critical Reviews in Toxicology·S A Wrighton, J C Stevens
Jan 1, 1990·Drug Metabolism Reviews·F Gaspari, M Bonati
Jun 1, 1988·The Journal of Pharmacy and Pharmacology·M E McManusD J Birkett
Sep 1, 1988·Clinical Pharmacokinetics·D J EdwardsM J Rybak
Dec 1, 1985·British Journal of Clinical Pharmacology·W J WijnandsC L Van Herwaarden
Jul 14, 1984·Lancet·W J WijnandsT B Vree
Jan 1, 1983·European Journal of Clinical Pharmacology·U Gundert-RemyE Weber
Mar 1, 1982·Clinical Pharmacology and Therapeutics·D D Tang-LiuS Riegelman
Oct 1, 1981·Clinical Pharmacology and Therapeutics·J J Grygiel, D J Birkett
Mar 1, 1995·British Journal of Clinical Pharmacology·H R HaF Follath
Jan 1, 1995·European Journal of Clinical Pharmacology·T KokufuK Nakajima

❮ Previous
Next ❯

Citations

Feb 28, 2003·Expert Opinion on Investigational Drugs·Darren AbbanatKaren Bush
Apr 21, 2011·Drugs·Gillian M Keating

❮ Previous
Next ❯

Related Concepts

Related Feeds

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.

© 2022 Meta ULC. All rights reserved